AllRock Bio Unveils Promising ROC-101 Phase 1 Data at ERS Congress AllRock Bio presents Phase 1 data for ROC-101 at ERS Congress, showing promising safety and efficacy for PAH and ILD-PH treatments.

AllRock Bio Unveils Promising ROC-101 Phase 1 Data at ERS Congress #USA #Natick #AllRock_Bio #ROC-101 #ERS_Congress

AllRock Bio Secures $50 Million in Series A Funding to Propel Innovative Pulmonary Hypertension Treatment AllRock Bio Inc. has successfully raised $50 million to advance ROC-101, its lead clinical candidate aimed at treating pulmonary hypertension and interstitial lung disease.

AllRock Bio Secures $50 Million in Series A Funding to Propel Innovative Pulmonary Hypertension Treatment #United_States #Natick #Pulmonary_Hypertension #AllRock_Bio #ROC-101